Invokamet XR (Canagliflozin/Metformin Hcl XR)

Indications

Invokamet-XR is a prescription medication used to treat type 2 diabetes in adults. It contains two active ingredients: canagliflozin and metformin hydrochloride extended release. By controlling high blood sugar, it helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke.

Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that helps to lower blood sugar levels by decreasing the amount of glucose absorbed by the kidneys. Metformin is a biguanide that helps to lower blood sugar levels by decreasing glucose production in the liver. By working together, canagliflozin and metformin can help patients better manage their blood sugar levels.

Use and Dosage

Invokamet XR is a tablet that should be taken orally, as directed by a healthcare provider. A patient should take it once a day with the morning meal and swallow the tablets whole. Patients should not crush or chew the tablets as doing so could release all the drugs at once, increasing the risk of side effects.

To get the most benefit from Invokamet XR, patients should take it regularly at the same time each day. Patients should drink plenty of fluids while taking this medication unless otherwise directed by their healthcare provider.

The dosage of Invokamet XR will depend on the patient's medical condition, response to treatment, and other medications they may be taking. Patients should tell their doctor and pharmacist about all the products they use, including prescription drugs, nonprescription drugs, and herbal products. To reduce the risk of side effects such as upset stomach, the healthcare provider may recommend that patients start with a low dose and gradually increase their dose. Patients should follow their healthcare provider's instructions carefully.

If a patient's condition does not improve or gets worse (blood sugar is too high or too low), they should inform their healthcare provider.

Side Effects

Common Side Effects of Invokamet-XR (Canagliflozin/Metformin Hcl XR):

• Genital infections
• Urinating more than usual
• Dizziness
• Nausea
• Stomach pain
• Vomiting
• Weakness

Serious Side Effects of Invokamet-XR (Canagliflozin/Metformin Hcl XR):

• Burning itching odor discharge pain tenderness redness or swelling of the genital or rectal area
• Confusion
• Difficulty breathing
• Feeling unwell
• Fever
• Heartbeats
• Hives
• Infections in your legs or feet
• Irregular
• Lightheadedness
• Little or no urination
• Loss of movement
• Pain or burning when you urinate
• Sores
• Swelling of your face lips tongue or throat
• Tenderness
• Ulcers
• Unusual drowsiness

Forms and Strength

Invokamet-XR (Canagliflozin/Metformin Hcl XR) is available in the following forms and strength:

Invokamet-XR: Tablet

• 50/500mg

Cautions

• Lactic acidosis: This is a rare but serious metabolic complication that can occur due to metformin accumulation.
• Increased risk of lower limb amputations: Canagliflozin may increase the risk of lower limb amputation, especially in patients with a history of amputation, peripheral vascular disease, neuropathy, or diabetic foot ulcers.
• Diabetic ketoacidosis: Canagliflozin may increase the risk of diabetic ketoacidosis, especially in patients who have a history of the condition or who have low insulin levels.
• Dehydration: Canagliflozin may increase the risk of dehydration, which can lead to a decrease in kidney function and an increase in the risk of kidney problems.
• Genital mycotic infections: Canagliflozin may increase the risk of genital mycotic infections, such as vaginal yeast infections or balanitis (an infection of the penis).
• Hypoglycemia: Canagliflozin may increase the risk of hypoglycemia (low blood sugar) when used in combination with certain other diabetes medications.
• Volume depletion: Canagliflozin may increase the risk of volume depletion, which can lead to a decrease in blood pressure.
• Kidney problems: Canagliflozin may increase the risk of kidney problems, especially in patients with pre-existing kidney disease or who are taking medications that affect kidney function.
• High potassium levels: Canagliflozin may increase the risk of elevated levels of potassium in the blood, especially in patients with kidney problems or who are taking medications that increase potassium levels.
• Pancreatitis: There have been reports of pancreatitis (inflammation of the pancreas) in patients taking canagliflozin.
• Hyperglycemia: Canagliflozin may increase the risk of hyperglycemia (high blood sugar) when used in combination with certain other diabetes medications.
• Urinary tract infections: Canagliflozin may increase the risk of urinary tract infections.

Frequently Asked Questions (FAQ)

Can Invokamet XR be used by pregnant women?

Invokamet XR should only be used during pregnancy if clearly needed, as it may cause harm to a developing fetus. Women who are pregnant or planning to become pregnant should discuss the potential risks and benefits of taking this medication with their healthcare provider.

Can Invokamet XR be used by breastfeeding women?

It is not known if Invokamet XR passes into breast milk, so women who are breastfeeding should talk to their healthcare provider before taking this medication.

What should I do if I miss a dose of Invokamet XR?

If you miss a dose of Invokamet XR, take it as soon as you remember. If it is close to the time for your next dose, skip the missed dose and take your next dose at the regular time. Do not double the dose to make up for the missed one.

Can Invokamet XR be used in children?

Invokamet XR has not been studied in pediatric patients, so it is not recommended for use in children.

Resources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205879s005lbl.pdf
• https://www.rxlist.com/invokamet-xr-drug.htm
• https://www.invokanahcp.com/invokamet-xr
• https://www.webmd.com/drugs/2/drug-172573/invokamet-xr-oral/details
• https://www.drugs.com/mtm/invokamet-xr.html
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205879s000lbl.pdf